Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development

International Journal of Cancer

Volumn 134, Issue 4, 2014, Pages 849-858

  Mamlouk, Soulafa ^a,e   Kalucka, Joanna ^a,f   Singh, Rashim Pal ^a   Franke, Kristin ^a   Muschter, Antje ^a   Langer, Anika ^a   Jakob, Christiane ^a   Gassmann, Max ^b,c   Baretton, Gustavo B ^a   Wielockx, Ben ^a,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

cytokines; prolyl hydroxylase 2; tumor associated immune cells

Indexed keywords

CYTOKINE; OXYGENASE; PROLYLHYDROXYLASE 2; UNCLASSIFIED DRUG;

ABLATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GENETICS; CANCER GROWTH; CANCER SIZE; CELL DEATH; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEFICIENCY; HEMATOPOIETIC SYSTEM; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

EID: 84890130054     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28409     Document Type: Article

References (46)

1. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
2. Kaelin WG, Jr, Ratcliffe PJ,. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402.
3. Wenger RH, Camenisch G, Stiehl DP, et al. HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting. Curr Pharm Des 2009; 15: 3886-94.
4. Chan DA, Kawahara TLA, Sutphin PD, et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15: 527-38.
5. Xue J, Li X, Jiao S, et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 2010; 138: 606-15.
6. Klotzsche-von Ameln A, Muschter A, Mamlouk S, et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFbeta. Cancer Res 2011; 71: 3306-16.
7. Klotzsche-von Ameln A, Muschter A, Heimesaat MM, et al. HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFbeta‚ activation. Cancer Biol Ther 2012; 13: 216-23.
8. Kerkar SP, Restifo NP,. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012; 72: 3125-30.
9. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
10. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-7.
11. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
12. Smyth MJ, Swann J, Cretney E, et al. NKG2D function protects the host from tumor initiation. J Exp Med 2005; 202: 583-8.
13. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
14. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
15. Biswas SK, Mantovani A,. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-96.
16. Franke K, Kalucka J, Mamlouk S, et al. HIF-1alpha is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2alpha-induced excessive erythropoiesis. Blood 2013; 121: 1436-45.
17. Singh RP, Franke K, Kalucka J, et al. HIF-prolyl hydroxylase 2 (PHD2) is a critical regulator of hematopoietic stem cell maintenance during steady-state and stress. Blood 2013; 121: 5158-66.
18. Andersen S, Donnem T, Stenvold H, et al. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PloS One 2011; 6: e23847.
19. Ruschitzka FT, Wenger RH, Stallmach T, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000; 97: 11609-13.
20. Abangan RS, Jr, Williams CR, Mehrotra M, et al. MCP1 directs trafficking of hematopoietic stem cell-derived fibroblast precursors in solid tumor. Am J Pathol 2010; 176: 1914-26.
21. Mantovani A, Sica A,. Macrophages, innate immunity and cancer: |balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-7.
22. Pollard JW,. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-8.
23. DeNardo DG, Andreu P, Coussens LM,. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 2010; 29: 309-16.
24. Clausen BE, Burkhardt C, Reith W, et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999; 8: 265-77.
25. Lee PP, Fitzpatrick DR, Beard C, et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 2001; 15: 763-74.
26. Rickert RC, Roes J, Rajewsky K,. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 1997; 25: 1317-18.
27. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
28. Scurr M, Gallimore A, Godkin A,. T cell subsets and colorectal cancer: discerning the good from the bad. Cell Immunol 2012; 279: 21-4.
29. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208: 469-78.
30. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67: 9518-27.
31. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98: 5181-6.
32. Okazaki T, Ebihara S, Asada M, et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008; 10: 932-9.
33. Paragh G, Kumar SM, Rakosy Z, et al. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 2009; 174: 1504-14.
34. Takeda Y, Costa S, Delamarre E, et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 2011; 479: 122-6.
35. Xue J, Li X, Jiao S, et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 2010; 138: 606-15.
36. Fu J, Taubman MB,. Prolyl hydroxylase EGLN3 regulates skeletal myoblast differentiation through an NF-kappaB-dependent pathway. J Biol Chem 2010; 285: 8927-35.
37. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006; 103: 18154-9.
38. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer |stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94: 1003-9.
39. Girardi M, Oppenheim D, Glusac EJ, et al. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol 2004; 122: 699-706.
40. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
41. Allavena P, Sica A, Solinas G, et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol/Hematol 2008; 66: 1-9.
42. Street SE, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-34.
43. Windbichler GH, Hausmaninger H, Stummvoll W, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000; 82: 1138-44.
44. Duluc D, Corvaisier M, Blanchard S, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 2009; 125: 367-73.
45. Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168: 689-95.
46. Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-73.